UCB SA (OTCMKTS:UCBJF) Given Average Rating of “Buy” by Analysts

Shares of UCB SA (OTCMKTS:UCBJF) have been given a consensus rating of “Buy” by the six ratings firms that are covering the firm, Marketbeat reports. Six analysts have rated the stock with a buy rating.

Several research firms have recently weighed in on UCBJF. Barclays reissued an “overweight” rating on shares of UCB in a research note on Tuesday, January 6th. Stephens reissued an “overweight” rating on shares of UCB in a research note on Thursday, January 15th. Wolfe Research began coverage on shares of UCB in a research note on Monday, February 23rd. They issued an “outperform” rating on the stock. Finally, The Goldman Sachs Group reissued a “buy” rating on shares of UCB in a research note on Monday, February 16th.

UCB Price Performance

OTCMKTS:UCBJF opened at $301.62 on Tuesday. The company’s 50-day moving average price is $310.80 and its 200-day moving average price is $296.24. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78. UCB has a twelve month low of $168.65 and a twelve month high of $345.39.

UCB Company Profile

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.